Other News Items
GWC
Technologies
505 S. Rosa Rd
Madison, WI 53719
USA 
608.441.2726
 
NEWS 2008

2008 Oct 09
New Application: Making Protein Arrays by CFM

GWC released today a new application note detailing the use of Continuous Flow Microspotting (CFM) to make protein arrays for analysis on GWC's label-free SPR imaging array system. The data show that CFM printing can generate functional protein arrays using very low concentrations of protein solution.

The note details the fabrication of 48-spot protein arrays using the CFM spotter from Wasatch Microfluidics. Typically, arrays fabricated manually or by robots are spotted at concentrations of 0.1-2mg/mL. However, in the new study, replicates of three proteins-β2-microglobulin, human serum albumin, and streptavidin-were arrayed using as little as 2µg/mL protein solution. Even at the lowest concentration, binding of antibodies to the protein probes was readily detectable, indicating that protein concentrations in the ng/mL range may be used for array fabricaton.

This work is important because many proteins of interest-such as monoclonal antibodies (mAbs)-may be available only at low concentrations. The CFM study shows there is no need for time-consuming and potentially damaging concentration measures when fabrication of arrays for label-free analysis is desired. Moreover, for mAb arrays, dramatic improvements in efficiency could be made by CFM spotting of unpurified mAbs at low concentrations directly onto a goat anti-mouse affinity surface. Plus, 96-spot arrays can be made on GWC's SPRchipT simply by fabricating two 48-spot arrays side by side, further enhancing the efficiency of label-free protein array analysis.

To learn more about this and other applications of GWC's label-free array system, please call 608.441.2726 or .

Return to the Top of the Page

2008 Sept 22
GWC Appoints Distributor for South East Asia

GWC Technologies Inc. today announced an agreement with Cybeles Life Science under which Cybeles will distribute GWC's label-free array systems in South East Asia. GWC's products are used in proteomics analysis, drug discovery research and diagnostics development. A key distinction of GWC's analysis systems is their superior throughput and greater experimental rigor, which results from their flexible array format.

GWC selected Cybeles Life Sciences based on Cybeles' successful experience distributing products and providing quality service in GWC's target markets. Cybeles will now be able to offer GWC's versatile label-free detection systems to researchers throughout Singapore, Malaysia and Thailand, delivering powerful and affordable solutions for the most rapidly growing areas of life science research.

According to Georg Gottmann, CEO of Cybeles, " We are proud to have the responsibility for the GWC product line. It will enable Cybeles to expand its business into the protein analysis market, delivering urgently needed capabilities to our expanding base of life science and medical researchers."

According to Tim Burland, GWC's President & CEO, "Cybeles Life Science has a team with more than 20 years proven experience in the molecular biotechnology market. The company has excellent application support and customer orientation, along with a successful track record in marketing, sales and support of products for biotechnology research. Moreover, Cybeles carries several lines complementary to GWC's products, adding significant value to the relationship." "Especially important," added Burland, "Cybeles staff have both the scientific background and the technical capabilities to provide the standard of service and support that GWC demands of its partners. We are delighted to welcome Cybeles Life Science to GWC's worldwide team."

About Cybeles Life Science: Established in 2002 in Heidelberg, Germany, Cybeles Life Science is a leading Company in the applied Biotechnology and molecular medicine market in South East Asia. With a product portfolio of instruments, reagents and supplies for molecular diagnostics and applied biotechnology, Cybeles provides complete solutions. Cybeles' subsidiaries in Malaysia, Singapore and Thailand provide application support and technical service for the South East Asian region. For more information, please contact info@Cybeles.de.

To learn more about GWC Technologies, please .

Return to the Top of the Page

2008 June 25
GWC Licenses Novel Label-Free Array Surface

GWC Technologies Inc. is pleased to announce it has signed an agreement with the Wisconsin Alumni Research Foundation (WARF) for an exclusive license to a new "carbon-on-metal" surface technology that will allow GWC's imaging systems to generate data more reliably than other products currently in the market. Details of the new technology, developed in the laboratory of Dr. Lloyd Smith, chemistry professor at the University of Wisconsin-Madison, recently were published by lead author Matthew Lockett and colleagues in the Journal of the American Chemical Society.

"Carbon-on-metal surfaces, in conjunction with GWC's label-free array systems, enhance the quality of information that can be obtained in studies of protein function. How proteins function is of great interest in drug discovery and life science research because proteins are central to how living cells are regulated at the molecular level," explained Smith.

GWC's scientific instruments use "SPR imaging," a method of analyzing many proteins at once. SPR imaging does not need the fluorescent tags or other chemical labels that traditional methods of protein analysis require. Fluorescent tags are problematic, because they can modify protein function, causing experimental artefacts. By contrast, experiments that use GWC's SPR imaging systems generate data that more accurately reflect protein function.

Stephen C. Weibel, GWC's director of engineering and a co-inventor of the new technology, explained, "The consumable chips utilized in our detection systems have relied on traditional gold surfaces, suitable for use in the research lab. This new and more robust surface allows the development of biochips and chemical sensors for use in medical diagnostics, environmental testing, and agriculture and food monitoring." He noted that the new surface is similar to the coating technology used on razor blades. "In addition to enabling the fabrication of high-density bio-chips, the new surfaces also are suitable for mass-spectrometry analysis of proteins captured on our arrays."

According to GWC's president and CEO, Tim Burland, the new surfaces will enable the company to implement many assays that are vitally important in drug discovery. Examples include the analysis of DNA-protein interactions on DNA arrays manufactured by so-called "on-chip" synthesis, and the study of protein-drug interactions using small molecule arrays made by combinatorial chemistry. He added that the company will be seeking corporate partners to bring the technology to the broadest possible market as quickly as possible.

About GWC Technologies, Inc. GWC Technologies develops, manufactures and markets scientific instruments for researchers in pharmaceutical, biotechnology and academic organizations worldwide. The company's products serve the rapidly growing "proteomics" market segment, providing detection systems that help scientists understand protein function to advance medicine and basic science. More information is available at: www.gwctechnologies.com

About Wisconsin Alumni Research Foundation: WARF supports world-class research at the University of Wisconsin-Madison by protecting the intellectual property of university faculty, staff and students, and licensing inventions resulting from their work. Through these efforts, university ideas benefit the public by bringing resources back to the university to continue the cycle of investment, research and invention. WARF was established in 1925 as the world's first university-based technology transfer office. More information is available at: www.warf.org.

Return to the Top of the Page

2008 May 05
GWC Appoints Distributor for India

GWC Technologies announced an agreement with Biotron Healthcare (India) P. Ltd. under which Biotron Healthcare will serve as exclusive distributor for GWC's label-free array systems in India. Previously niche products, "label-free" systems are now taking center stage in proteomics analysis, drug discovery research and diagnostics development, where they deliver special benefits over traditional detection systems. A key distinction of label-free systems is that they avoid the use of fluorescent labels that can cause experimental artefacts. Label-free analysis also allows more information to be collected about target molecules than do conventional scientific instruments.

A key distinction of GWC's label-free systems is their flexible array format, which delivers superior throughput and greater experimental rigor than do alternative formats. Biotron Healthcare will now be able to offer GWC's versatile label-free detection systems to researchers throughout India, delivering powerful and affordable solutions for the most rapidly growing areas of life science research. According to Tim Burland, GWC's President & CEO, "Biotron Healthcare has a broad reach across the Indian subcontinent with eight sales offices in addition to their headquarters in Mumbai. The company is experienced in marketing, sales and support of scientific instruments, research reagents and research supplies, including several product lines complementary to GWC's products." "Equally important," added Burland, "Biotron staff have both the scientific background and the technical capabilities needed to provide the standard of service and support that GWC demands of its partners. We are delighted to welcome Biotron Healthcare to GWC's worldwide team."

About Biotron Healthcare (India) P. Ltd: Established in 1997, Biotron Healthcare (India) P. Ltd is an experienced distributor of equipment, reagents and supplies for drug discovery, genomics, molecular diagnostics and biotechnology markets in India. The company provides technical support and equipment maintenance for users of its products in universities, testing laboratories, medical research facilities and pharmaceutical companies. The relationship with GWC will enable Biotron to expand its business throughout India. For more information, please contact info@biotronhealthcare.com.

About GWC Technologies: GWC Technologies, Inc. is based in Madison, Wisconsin, USA. GWC develops, manufactures, and markets label-free analysis systems for the drug discovery, life science research, diagnostics and materials science markets. Products are sold direct in North America, and through distributors and OEM partners elsewhere. Over 50% of GWC's sales are exports, and the company's products are in use in over a dozen countries.

Return to the Top of the Page

2008 Mar 05
SpotReady™ Chip Patent Issued

GWC Technologies Inc. is pleased to announce the issuance of US Patent 7,332,329, relating to technology that GWC licenses exclusively from the Wisconsin Alumni Research Foundation (WARF), the private, non-profit patenting and licensing organization of the University of Wisconsin - Madison. Using this technology, GWC has developed the “SpotReady™” line of biochips for use with the company’s scientific instruments. SpotReady™ chips allow researchers to prepare arrays of proteins and other molecules without the need for expensive and often troublesome spotting equipment typically required for other array systems. “Our customers really appreciate the convenience and value of these chips in saving them time and money”, said Voula Kodoyianni, PhD, a co-inventor and GWC’s chief scientific officer. “Moreover, SpotReady™ arrays require much less sample than do arrays made with automated spotters, facilitating analysis of samples that are very precious or in very short supply”, she added.

The SpotReady™ technology resulted from a collaboration between GWC Technologies and the laboratory of Robert Corn, a co-founder of GWC Technologies who is now a professor of chemistry at the University of California, Irvine. The SpotReady™ idea was developed when Dr. Corn was at the University of Wisconsin-Madison. Tim Burland, GWC’s President and CEO, said that this technology is another example of the symbiotic relationship between the University of Wisconsin and local technology companies. “The strong scientific expertise along with substantial technical and manufacturing resources in our region helped us to commercialize this product within weeks of WARF filing the patent application”, he explained. “It is also tremendously helpful to have WARF as a partner in this type of project. Their intellectual property expertise is first class, and licenses to patents of this quality add significantly to the value of companies like ours”, he added.

For more information, please contact Tim Burland, President & CEO, GWC Technologies Inc., 608.441.2722.

Return to the Top of the Page

2008 Mar 01
Epitope analysis protocol now available for the SPRimagerŽII
GWC Technologies is pleased to announce publication of our assay tutorial in the March 1, 2008 issue of Genetic Engineering News. The tutorial reports on three applications, including a new protocol for antibody epitope analysis using the SPRimagerŽII system. This label-free method allows multiple antibodies raised against the same antigen to be characterized on a single array.

The report details the method’s application to a set of mouse monoclonal antibodies, though it is readily adaptable to antibodies from any species. This approach to epitope characterization is ideal for identifying capture and detection antibody pairs for use in proteomics and biomarker discovery projects—it is a direct functional test that leaves no doubt as to the availability of the second epitope when the first epitope is already bound to antigen.

For more information about this or other applications of GWC's label-free array systems, please contact .

Return to the Top of the Page

2008 Jan 31
GWC's Label-Free Array Platform Used To Monitor Interactions Between Viral Capsid Protein and Regulatory RNA Elements
Research describing a new method to monitor the interaction of viral capsid proteins with specific RNA sequences was recently published in the Journal of Virological Methods. Bradley Garcia and Robert Goodman used GWC’s label-free SPR imaging platform to analyze TMV capsid protein binding to nucleic acid arrays. The TMV proteins bound specifically to viral RNAs containing the Origin of Assembly Sequence (OAS).

For these experiments, Garcia and Goodman made an RNA array by first fabricating a simple DNA oligonucleotide array designed to hybridize to viral RNAs of interest. Capture of viral RNAs 1.4 to 1.5 kilobases long on the DNA array was then confirmed by monitoring hybridization of the RNA to the DNA arrays on the SPRimagerŽII in real time. Binding of 20S viral capsid protein aggregates to these RNA arrays was then monitored in the same experiment, and as expected, the capsid proteins bound only to the RNAs containing the OAS.

This work is important because it shows how both specificity and kinetics of the interactions between viral capsid proteins and kilobase-scale nucleic acids can be determined efficiently for multiple sequences in a single experimental analysis using the SPRimager®II system. It also illustrates once more the power and versatility of GWC’s label-free array platform for analysis of multiple types of analytes.

For more information about GWC's label-free array systems, please contact .

Return to the Top of the Page
©2010 GWC Technologies
Contact our with any questions or comments.